Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 48.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,242 shares of the company’s stock after purchasing an additional 1,056 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Medidata Solutions were worth $205,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Summit Creek Advisors LLC bought a new position in Medidata Solutions during the fourth quarter valued at $5,137,000. AMP Capital Investors Ltd bought a new position in Medidata Solutions during the third quarter valued at $2,194,000. KAMES CAPITAL plc grew its holdings in Medidata Solutions by 54.6% during the fourth quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock valued at $1,617,000 after purchasing an additional 9,012 shares during the period. Zions Bancorporation bought a new position in Medidata Solutions during the third quarter valued at $256,000. Finally, Schwab Charles Investment Management Inc. grew its holdings in Medidata Solutions by 38.3% during the third quarter. Schwab Charles Investment Management Inc. now owns 326,950 shares of the company’s stock valued at $25,522,000 after purchasing an additional 90,572 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.
Shares of Medidata Solutions Inc (NASDAQ:MDSO) opened at $66.46 on Friday. The stock has a market capitalization of $3,955.97, a price-to-earnings ratio of 77.59, a price-to-earnings-growth ratio of 3.42 and a beta of 1.58. Medidata Solutions Inc has a 12-month low of $54.36 and a 12-month high of $85.92. The company has a current ratio of 1.50, a quick ratio of 3.37 and a debt-to-equity ratio of 0.20.
In related news, CFO Rouven Bergmann sold 2,000 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $65.40, for a total value of $130,800.00. Following the sale, the chief financial officer now owns 91,775 shares in the company, valued at $6,002,085. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Carlos Dominguez sold 9,066 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $66.85, for a total value of $606,062.10. Following the completion of the sale, the director now owns 66,020 shares in the company, valued at approximately $4,413,437. The disclosure for this sale can be found here. Insiders sold 20,066 shares of company stock worth $1,346,622 in the last quarter. 5.80% of the stock is currently owned by company insiders.
Several brokerages have weighed in on MDSO. Zacks Investment Research lowered Medidata Solutions from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Needham & Company LLC reduced their price objective on Medidata Solutions to $75.00 and set a “buy” rating for the company in a report on Friday, February 9th. Morgan Stanley dropped their target price on Medidata Solutions from $86.00 to $79.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. Royal Bank of Canada set a $82.00 target price on Medidata Solutions and gave the stock a “hold” rating in a research report on Thursday, February 8th. Finally, BidaskClub upgraded Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Four investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $82.07.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.